US Stock MarketDetailed Quotes
AYTU Aytu BioPharma
- 3.0600
- +0.0500+1.66%
Close May 6 16:00 ET
17.04MMarket Cap-763P/E (TTM)
3.1700High3.0400Low43.67KVolume3.0900Open3.0100Pre Close134.99KTurnover1.15%Turnover RatioLossP/E (Static)5.57MShares3.500052wk High0.52P/B11.62MFloat Cap1.380052wk Low--Dividend TTM3.80MShs Float27279.9864Historical High--Div YieldTTM4.32%Amplitude1.3800Historical Low3.0910Avg Price1Lot Size
Aytu BioPharma Key Stats
Quarterly+Annual
YOY
| (Q2)Dec 31, 2023 | (Q1)Sep 30, 2023 | (FY)Jun 30, 2023 | (Q4)Jun 30, 2023 | (Q3)Mar 31, 2023 | (Q2)Dec 31, 2022 | (Q1)Sep 30, 2022 | (FY)Jun 30, 2022 | (Q4)Jun 30, 2022 | (Q3)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -12.73%22.93M | -20.09%22.1M | 11.10%107.4M | 11.96%30.73M | -6.06%22.73M | 13.64%26.28M | 26.30%27.66M | 47.29%96.67M | 16.89%27.45M | 79.48%24.2M |
| Operating revenue | -12.73%22.93M | -20.09%22.1M | 11.10%107.4M | 11.96%30.73M | -6.06%22.73M | 13.64%26.28M | 30.82%27.66M | 47.29%96.67M | 16.89%27.45M | 79.48%24.2M |
| Cost of revenue | -25.09%6.73M | -23.98%7.32M | -8.15%40.77M | -3.47%12.17M | -13.23%9.99M | -17.00%8.99M | 1.93%9.62M | 21.83%44.39M | 3.47%12.61M | -17.38%11.51M |
| Gross profit | -6.30%16.2M | -18.01%14.78M | 27.44%66.63M | 25.08%18.56M | 0.45%12.74M | 40.60%17.29M | 44.77%18.03M | 79.05%52.28M | 31.36%14.84M | 2,906.64%12.69M |
| Operating expense | -35.59%13.84M | -17.26%16.29M | -10.66%78.96M | -28.21%15.76M | -0.50%22.04M | -8.93%21.49M | -4.91%19.69M | 31.06%88.39M | -17.96%21.95M | 51.96%22.15M |
| Selling and administrative expenses | -35.33%12.02M | -17.48%14.38M | 0.28%70.08M | -18.97%14.1M | 15.10%19.98M | 5.48%18.58M | -0.51%17.42M | 25.22%69.88M | -16.10%17.4M | 37.79%17.36M |
| -Selling and marketing expense | -37.73%6.58M | -26.53%7.42M | 7.06%41.45M | -20.28%7.98M | 31.42%12.8M | 9.32%10.56M | 8.66%10.1M | 27.73%38.71M | -17.79%10.01M | 47.69%9.74M |
| -General and administrative expense | -32.17%5.44M | -5.00%6.96M | -8.14%28.63M | -17.19%6.11M | -5.76%7.18M | 0.82%8.02M | -10.88%7.32M | 22.22%31.17M | -13.68%7.38M | 26.91%7.62M |
| Research and development costs | -69.36%524K | -43.23%604K | -67.66%4.1M | -85.71%465K | -73.92%856K | -61.79%1.71M | -35.59%1.06M | 125.18%12.66M | -31.72%3.25M | 741.54%3.28M |
| Depreciation amortization depletion | 8.51%1.3M | 9.11%1.31M | -18.07%4.79M | -7.94%1.2M | -20.35%1.2M | -20.40%1.2M | -22.12%1.2M | -2.75%5.84M | 3.43%1.3M | -5.11%1.5M |
| -Depreciation and amortization | 8.51%1.3M | 9.11%1.31M | -18.07%4.79M | -7.94%1.2M | -20.35%1.2M | -20.40%1.2M | -22.12%1.2M | -2.75%5.84M | 3.43%1.3M | -5.11%1.5M |
| Operating profit | 156.38%2.36M | 9.01%-1.5M | 65.85%-12.33M | 139.54%2.81M | 1.77%-9.29M | 62.87%-4.19M | 79.95%-1.65M | 5.59%-36.1M | 54.03%-7.1M | 37.04%-9.46M |
| Net non-operating interest income expense | ||||||||||
| Other net income (expense) | 29.76%-1.76M | -794.96%-6.62M | 93.51%-4.72M | 41.39%-5.27M | 104.77%2.09M | -872.76%-2.5M | 104.83%952K | -267.79%-72.79M | -174.52%-8.99M | -319.49%-43.83M |
| Gain on sale of security | -141.13%-577K | -369.60%-5.91M | 198.63%4.79M | -185.24%-1.37M | 36,857.14%2.57M | --1.4M | --2.19M | --1.61M | --1.61M | ---7K |
| Special income (charges) | --0 | --0 | 93.57%-4.74M | 109.01%887K | 98.90%-481K | ---2.68M | 99.21%-155K | -315.07%-73.63M | -254.21%-9.84M | -337.20%-43.83M |
| -Less：Restructuring and merger&acquisition | --0 | --0 | 41.45%-969K | -311.97%-3.99M | 140.02%481K | --75K | -29.22%155K | -149.46%-1.66M | 86.27%-969K | -121.00%-1.2M |
| -Less:Impairment of capital assets | ---- | ---- | --0 | -325.50%-2.6M | --0 | ---- | ---- | 413.08%65.8M | -86.48%1.15M | 951.07%45.2M |
| -Less:Other special charges | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -110.77%-169K | --0 | ---169K |
| -Write off | --0 | ---- | -40.92%5.71M | ---- | ---- | --2.6M | ---- | --9.66M | ---- | ---- |
| Other non- operating income (expenses) | 3.99%-1.18M | 34.59%-709K | -531.31%-4.78M | ---- | ---- | -377.82%-1.23M | -2,610.00%-1.08M | 63.07%-757K | ---- | ---- |
| Income before tax | 109.08%608K | -1,058.35%-8.12M | 84.34%-17.05M | 84.73%-2.46M | 86.49%-7.2M | 42.06%-6.69M | 97.49%-701K | -87.64%-108.89M | 14.14%-16.09M | -109.31%-53.29M |
| Income tax | 828K | 0 | 0 | 0 | 0 | 0 | 0 | -142.47%-110K | 0 | 0 |
| Net income | 96.71%-220K | -1,058.35%-8.12M | 84.33%-17.05M | 84.73%-2.46M | 86.49%-7.2M | 42.04%-6.69M | 97.48%-701K | -86.62%-108.78M | 15.31%-16.09M | -109.31%-53.29M |
| Net income continuous Operations | 96.71%-220K | -1,058.35%-8.12M | 84.33%-17.05M | 84.73%-2.46M | 86.49%-7.2M | 42.04%-6.69M | 97.48%-701K | -86.62%-108.78M | 15.31%-16.09M | -109.31%-53.29M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | 96.71%-220K | -1,058.35%-8.12M | 84.33%-17.05M | 84.73%-2.46M | 86.49%-7.2M | 42.04%-6.69M | 97.48%-701K | -86.62%-108.78M | 15.31%-16.09M | -109.31%-53.29M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | 96.71%-220K | -1,058.35%-8.12M | 84.33%-17.05M | 84.73%-2.46M | 86.49%-7.2M | 42.04%-6.69M | 97.48%-701K | -86.62%-108.78M | 15.31%-16.09M | -109.31%-53.29M |
| Basic earnings per share | 98.14%-0.04 | -428.57%-1.48 | 93.10%-5.11 | 93.98%-0.59 | 94.62%-1.93 | 75.40%-2.15 | 99.94%-0.28 | -6.34%-74.01 | 39.51%-9.8 | -27.30%-35.9 |
| Diluted earnings per share | 98.14%-0.04 | -428.57%-1.48 | 93.10%-5.11 | 93.98%-0.59 | 94.62%-1.93 | 75.40%-2.15 | 99.94%-0.28 | -6.34%-74.01 | 39.51%-9.8 | -27.30%-35.9 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg